Miura T - Search Results

1

Development of a Method for Converting a TAK1 Type I Inhibitor into a Type II or c-Helix-Out Inhibitor by Structure-Based Drug Design (SBDD).

Muraoka T, Ide M, Irie M, Morikami K, Miura T, Nishihara M, Kashiwagi H. Muraoka T, et al. Among authors: miura t. Chem Pharm Bull (Tokyo). 2016;64(11):1622-1629. doi: 10.1248/cpb.c16-00606. Chem Pharm Bull (Tokyo). 2016. PMID: 27803473 Free article.

2

Discovery of a potent and highly selective transforming growth factor β receptor-associated kinase 1 (TAK1) inhibitor by structure based drug design (SBDD).

Muraoka T, Ide M, Morikami K, Irie M, Nakamura M, Miura T, Kamikawa T, Nishihara M, Kashiwagi H. Muraoka T, et al. Among authors: miura t. Bioorg Med Chem. 2016 Sep 15;24(18):4206-4217. doi: 10.1016/j.bmc.2016.07.006. Epub 2016 Jul 6. Bioorg Med Chem. 2016. PMID: 27448772

3

Identification of a selective inhibitor of transforming growth factor β-activated kinase 1 by biosensor-based screening of focused libraries.

Miura T, Matsuo A, Muraoka T, Ide M, Morikami K, Kamikawa T, Nishihara M, Kashiwagi H. Miura T, et al. Bioorg Med Chem Lett. 2017 Feb 15;27(4):1031-1036. doi: 10.1016/j.bmcl.2016.12.064. Epub 2016 Dec 29. Bioorg Med Chem Lett. 2017. PMID: 28109791

4

Design and evaluation of azaindole-substituted N-hydroxypyridones as glyoxalase I inhibitors.

Chiba T, Ohwada J, Sakamoto H, Kobayashi T, Fukami TA, Irie M, Miura T, Ohara K, Koyano H. Chiba T, et al. Among authors: miura t. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7486-9. doi: 10.1016/j.bmcl.2012.10.045. Epub 2012 Oct 17. Bioorg Med Chem Lett. 2012. PMID: 23122816

5

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, Saborowski M, Kastenhuber E, Fellmann C, Ohara K, Morikami K, Miura T, Lukacs C, Ishii N, Lowe S, Rosen N. Lito P, et al. Among authors: miura t. Cancer Cell. 2014 May 12;25(5):697-710. doi: 10.1016/j.ccr.2014.03.011. Epub 2014 Apr 17. Cancer Cell. 2014. PMID: 24746704 Free PMC article.

6

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.

Fukuzawa T, Sampei Z, Haraya K, Ruike Y, Shida-Kawazoe M, Shimizu Y, Gan SW, Irie M, Tsuboi Y, Tai H, Sakiyama T, Sakamoto A, Ishii S, Maeda A, Iwayanagi Y, Shibahara N, Shibuya M, Nakamura G, Nambu T, Hayasaka A, Mimoto F, Okura Y, Hori Y, Habu K, Wada M, Miura T, Tachibana T, Honda K, Tsunoda H, Kitazawa T, Kawabe Y, Igawa T, Hattori K, Nezu J. Fukuzawa T, et al. Among authors: miura t. Sci Rep. 2017 Apr 24;7(1):1080. doi: 10.1038/s41598-017-01087-7. Sci Rep. 2017. PMID: 28439081 Free PMC article.

7

Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.

Miura T, Fukami TA, Hasegawa K, Ono N, Suda A, Shindo H, Yoon DO, Kim SJ, Na YJ, Aoki Y, Shimma N, Tsukuda T, Shiratori Y. Miura T, et al. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5778-83. doi: 10.1016/j.bmcl.2011.08.001. Epub 2011 Aug 6. Bioorg Med Chem Lett. 2011. PMID: 21875802

8

Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.

Isshiki Y, Kohchi Y, Iikura H, Matsubara Y, Asoh K, Murata T, Kohchi M, Mizuguchi E, Tsujii S, Hattori K, Miura T, Yoshimura Y, Aida S, Miwa M, Saitoh R, Murao N, Okabe H, Belunis C, Janson C, Lukacs C, Schück V, Shimma N. Isshiki Y, et al. Among authors: miura t. Bioorg Med Chem Lett. 2011 Mar 15;21(6):1795-801. doi: 10.1016/j.bmcl.2011.01.062. Epub 2011 Jan 21. Bioorg Med Chem Lett. 2011. PMID: 21316218

9

Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors.

Suda A, Kawasaki K, Komiyama S, Isshiki Y, Yoon DO, Kim SJ, Na YJ, Hasegawa K, Fukami TA, Sato S, Miura T, Ono N, Yamazaki T, Saitoh R, Shimma N, Shiratori Y, Tsukuda T. Suda A, et al. Among authors: miura t. Bioorg Med Chem. 2014 Jan 15;22(2):892-905. doi: 10.1016/j.bmc.2013.11.036. Epub 2013 Nov 25. Bioorg Med Chem. 2014. PMID: 24369839

10

Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.

Ishii N, Harada N, Joseph EW, Ohara K, Miura T, Sakamoto H, Matsuda Y, Tomii Y, Tachibana-Kondo Y, Iikura H, Aoki T, Shimma N, Arisawa M, Sowa Y, Poulikakos PI, Rosen N, Aoki Y, Sakai T. Ishii N, et al. Among authors: miura t. Cancer Res. 2013 Jul 1;73(13):4050-4060. doi: 10.1158/0008-5472.CAN-12-3937. Epub 2013 May 10. Cancer Res. 2013. PMID: 23667175 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,044 results

Search Page